Results 161 to 170 of about 54,075 (219)

Cost-utility and budget impact analysis of biosimilar trastuzumab for early-stage HER2-positive breast cancer in Thailand: an updated evaluation supporting expanded access. [PDF]

BMC Health Serv Res
Lochid-Amnuay S, Kongsakon R.
europepmc   +1 more source

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2⁺ breast cancer: TBCRC049 phase 2 study results. [PDF]

Nat Cancer
Murthy RK, O'Brien BJ, Berry DA, Singareeka-Raghavendra A, Monroe MG, Johnson J, White J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Riley K, Melisko M, Morikawa A, Ferguson SD, de Groot JF, Krop IE, Valero V, Rimawi MF, Wolff AC, Tripathy D, Lin NU, Stringer-Reasor EM.   +21 more
europepmc   +1 more source

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. [PDF]

Clin Cancer Res
Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, de Claro RA, Pazdur R, Lemery SJ.   +8 more
europepmc   +1 more source

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study. [PDF]

Ther Adv Med Oncol
Sahin TK, Kemik F, Muglu H, Acikgöz Yildiz B, Biter S, Tunbekici S, Oruc A, Guren AK, Kaban K, Guzel HG, Erol C, Aykan MB, Koylu B, Ekinci OB, Deliktas Onur I, Kalem A, Altunok O, Seyyar M, Guney B, Akdogan O, Ismayilov R, Ardic FS, Yazici M, Majidova N, Turker S, Esin E, Cabuk D, Yasar HA, Oguz A, Yazici O, Gursu RU, Yılmaz M, Yesil Cinkir H, Ates O, Celik E, Karadurmus N, Demirci U, Ozturk B, Mandel NM, Bayoglu IV, Araz M, Goker E, Bayram E, Erdem D, Selcukbiricik F, Basaran G, Sezer A, Dogu GG, Kemal Y, Bilici A, Gunduz S, Guven DC, Aksoy S.   +52 more
europepmc   +1 more source

HER2-directed therapy in metastatic vulvar empd-a report of two cases and narrative review. [PDF]

AME Case Rep
Gorecki G, Antonios B, Rajrajan S, Babu K, Nakayama J, Hilton C.   +5 more
europepmc   +1 more source

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer. [PDF]

NPJ Breast Cancer
Van Mackelenbergh MT, Pfarr N, Weber K, Untch M, Solbach C, Schneeweiss A, Jank P, Blohmer J, Treue D, Schmatloch S, Lehmann A, Hanusch C, Link T, Sers C, Bjelic-Radisic V, Hummel M, Huober J, Schmitt WD, Fasching PA, Aktas B, Rhiem K, Reinisch M, Nekljudova V, Denkert C, Loibl S.   +24 more
europepmc   +1 more source

Evolving treatment strategies for HER2-altered non-small-cell lung cancer: the rise of TKIs and ADCs. [PDF]

Front Oncol
Balli S, Basoglu T, Ozdogan M.
europepmc   +1 more source

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer. [PDF]

Breast Cancer Res Treat
de Moura Leite L, de Almeida GR, Tavares MC, Cesca MG, Campos FAB, de Oliveira FA, Dornellas DMS, Saldanha EF, Guimarães PT, de Arruda DDS, de Held MFSD, Viana RL, Moura FGR, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Sanches SM, de Lima VCC.   +19 more
europepmc   +1 more source

Complete and Rapid NMR Characterization of Therapeutic Monoclonal Antibodies via Differential Labeling of Fab Fragments in <i>Escherichia coli</i>. [PDF]

Anal Chem
Gagné D, Aubin Y.
europepmc   +1 more source